Bioshares wrote a short piece on BNO. Rated a speculative buy (class A) but importantly gave a summary table of competing PhII studies and expected completion date. The publication says it will review the programs in a future issue. It also mentioned the strategy to get out of oncology. I'll keep my eye open for the next 'review' piece. Meanwhile the SP is tracking nicely and the analysts' reports are all positive also. GLTA
Add to My Watchlist
What is My Watchlist?